



ASX Release

23 March 2017

ZELDA THERAPEUTICS LIMITED  
ACN 103 782 378

Level 45  
108 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [enquiries@zeldatherapeutics.com](mailto:enquiries@zeldatherapeutics.com)  
Web: [www.zeldatherapeutics.com](http://www.zeldatherapeutics.com)

#### **Contacts**

##### **Corporate**

Mr Harry Karelis  
Executive Chairman  
+61 413 056 328  
[hkarelis@zeldatherapeutics.com](mailto:hkarelis@zeldatherapeutics.com)

##### **Investors**

Dr Stewart Washer  
Executive Director  
+61 418 288 212  
[swasher@zeldatherapeutics.com](mailto:swasher@zeldatherapeutics.com)

#### **Directors**

Mr Harry Karelis  
Dr Stewart Washer  
Ms Mara Gordon  
Mr Jason Peterson

#### **ASX Code:**

ZLD

#### **Ordinary Shares:**

669,127,649

#### **Options:**

48,000,000

6,000,000 (\$0.04 - 6/2/2020 -  
subject to vesting conditions)  
2,000,000 (\$0.04 - 6/2/2020)  
40,000,000 (\$0.03125-17/11/2021)

## **Zelda Therapeutics Expands its Research Programme Internationally with Clinical Trials Commencing in Chile**

- **Zelda Therapeutics will launch its clinical trial programme in Chile in the second half of this year**
- **Clinical trials to target insomnia and eczema**
- **Leverages relationship with ASX-listed AusCann which through its joint venture in Chile, DayaCann, is the only licensed grower of medical cannabis in Chile**
- **Zelda intends to register products for sale in Chile should trials be successful providing a pathway to maiden revenues**
- **Chile has a robust regulatory environment and provides a very cost effective location to conduct clinical trials**

The Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** is pleased to announce it has expanded its clinical trial programme to include two new trials to begin in the second half of CY2017 in Chile. The trials will target insomnia and eczema, two significantly sized markets with combined global value of approximately \$8 billion in 2016 (*Source: GBI Research and Reuters*).

Chile has made significant progress in its legal framework to recognize the importance of medical cannabis research, allowing the production of medical cannabis under strict regulatory controls for the treatment of medical conditions, since 2014. The country also provides a cost-effective location for Zelda to conduct clinical trials.

Zelda has identified key clinicians and sites within Chile where the trials will take place, with clinical trial protocols being finalised for submission to the relevant human ethics committees for approval. More details will be provided in due course.

To streamline the Chilean clinical trials and facilitate the research programme, Zelda will leverage its relationship with AusCann Group Holdings Ltd (ASX:AC8) through its Chilean joint-venture DayaCann and will also work together with Chilean non-profit patient advocate group Fundacion Daya. DayaCann is the only licensed producer of medicinal cannabis in Chile and is expected to harvest its first crop in the second quarter of CY2017.

These trials will form part of the registration protocols with Chile's Institute of Public Health to demonstrate efficacy before the medicinal cannabis products can be registered and marketed within Chile. The Company expects to conclude the trials by the end of CY2017 with data available shortly thereafter. The Company intends to commence the product registration process to allow Zelda to sell clinically approved products as soon as positive trial data is in hand. This provides a pathway to potential revenue generation as early as 2018.

Australia and Chile have a long history of trade and enjoy a strong bilateral relationship. Chile is Australia's third-largest trading partner in Latin America, with two-way goods and services trade totaling \$1.8 billion in 2013-2014 and over 120 Australian companies active in Chile<sup>1</sup>.

<sup>1</sup> Source: Department of Foreign Affairs, Australian Federal Government

The Company is continuing discussions with GMP (good manufacturing practice) manufacturers in Chile who would be able to manufacture the formulations as well as potential distribution partners upon the formulations receiving registration approval. The registration in Chile also has the potential to open up further opportunities in other South American markets where medical cannabis is permitted, including the sizable Brazilian market.

Harry Karelis, Executive Chairman said *“The sleep and dermatitis markets represent significant opportunities for Zelda Therapeutics. The proposed clinical trials in Chile will complement our other trial and pre-clinical research activities. There are tremendous opportunities in the rapidly expanding global medical cannabis sector and we are absolutely focused on maintaining Zelda’s position as a leader in the field. Our aim is to provide patients in need with access to high quality and affordable medicines.”*

**Tim Slate**  
**Company Secretary**

**About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (*Aunt Zelda’s*) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has embarked on a programme of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.